BARINTHUS BIOTHERAPEUTICS PLC Cash and Restricted Cash
BARINTHUS BIOTHERAPEUTICS PLC (BRNS) had Cash and Restricted Cash of $59.63 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $59.63M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $67.19M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $71.85M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $75.67M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $59.63M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $67.19M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $71.85M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $75.67M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $87.78M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $100.58M 10-Q · filed 2026-04-30 |
| 2024-12-31 | $112.40M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $106.10M 10-Q · filed 2025-11-07 |
| 2024-06-30 | $117.77M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $129.97M 10-Q · filed 2025-05-07 |
| 2023-12-31 | $142.09M 10-K · filed 2026-03-13 |
| 2023-09-30 | $160.31M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $173.03M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $191.33M 10-Q · filed 2024-05-13 |
| 2022-12-31 | $194.38M 10-K · filed 2025-03-20 |
| 2022-09-30 | $200.10M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $192.33M 10-Q · filed 2023-08-10 |
| 2022-03-31 | $200.60M 10-Q · filed 2023-05-12 |
| 2021-12-31 | $214.05M 10-K · filed 2024-03-20 |
| 2021-09-30 | $233.87M 10-Q · filed 2022-11-10 |
| 2021-06-30 | $243.62M 10-Q · filed 2022-08-09 |
| 2021-03-31 | $155.94M 10-Q · filed 2022-05-11 |
| 2020-12-31 | $43.27M 10-K · filed 2023-03-24 |
| 2020-09-30 | $29.63M 10-Q · filed 2021-11-12 |
| 2020-06-30 | $5.28M 10-Q · filed 2021-08-12 |
| 2020-03-31 | $6.43M 10-Q · filed 2021-06-14 |
| 2019-12-31 | $11.43M 10-K · filed 2022-03-25 |